Compass Pathways (NASDAQ:CMPS) Stock Lifted to Sell by Wall Street Zen

Key Points

• Wall Street Zen upgraded Compass Pathways from “strong sell” to “sell,” while broader analyst sentiment remains more positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $23.14.
• Several firms maintain Buy or Outperform ratings, with price targets ranging from $18 to $25; one analyst rates the shares Strong Buy, 14 Buy, one Hold, and one Sell.
• Compass reported a quarterly loss of $0.31 per share, narrower than the consensus estimate of a $0.39 loss. Shares opened at $8.61, below their 50-day average of $12.32.

Compass Pathways (NASDAQ:CMPS - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued on Sunday, Wall Street Zen reports.

CMPS has been the subject of several other research reports. Morgan Stanley lifted their price target on Compass Pathways from $17.00 to $18.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Oppenheimer restated an "outperform" rating and set a $20.00 price objective on shares of Compass Pathways in a research report on Tuesday. BTIG Research reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Compass Pathways in a research note on Tuesday, November 3rd. B. Riley Financial raised their price objective on Compass Pathways from $17.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, Jefferies Financial Group reiterated a "buy" rating on shares of Compass Pathways in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Compass Pathways currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.14.

Compass Pathways Stock Performance

Shares of NASDAQ:CMPS opened at $8.61 on Friday. The firm has a fifty day simple moving average of $12.32 and a two-hundred day simple moving average of $10.41. Compass Pathways has a 52 week low of $4.88 and a 52 week high of $15.87. The company has a quick ratio of 1.30, a current ratio of 1.50 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $1.19 billion, a P/E ratio of -2.47 and a beta of 2.43.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.08. On average, analysts expect that Compass Pathways will post -0.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

Several institutional investors have recently made changes to their positions in CMPS. Ancora Advisors LLC purchased a new position in shares of Compass Pathways during the 2nd quarter worth about $43,000. EverSource Wealth Advisors LLC raised its position in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company's stock worth $26,000 after purchasing an additional 1,920 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Compass Pathways in the 3rd quarter worth about $85,000. Parallel Advisors LLC lifted its stake in Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company's stock worth $40,000 after purchasing an additional 7,183 shares during the last quarter. Finally, North Star Investment Management Corp. lifted its stake in Compass Pathways by 23.9% in the third quarter. North Star Investment Management Corp. now owns 9,317 shares of the company's stock worth $116,000 after purchasing an additional 1,800 shares during the last quarter. Institutional investors own 46.19% of the company's stock.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company's lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.